Verona Pharma Statistics
Total Valuation
Verona Pharma has a market cap or net worth of $5.31 billion. The enterprise value is $5.03 billion.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Verona Pharma has 84.98 million shares outstanding. The number of shares has increased by 2.87% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 84.98M |
| Shares Change (YoY) | +2.87% |
| Shares Change (QoQ) | +1.74% |
| Owned by Insiders (%) | 4.24% |
| Owned by Institutions (%) | 68.17% |
| Float | 61.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 120.92 |
| Forward PS | 18.32 |
| PB Ratio | 25.94 |
| P/TBV Ratio | 25.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 119.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.63, with a Debt / Equity ratio of 1.12.
| Current Ratio | 10.63 |
| Quick Ratio | 10.24 |
| Debt / Equity | 1.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.42 |
Financial Efficiency
Return on equity (ROE) is -76.42% and return on invested capital (ROIC) is -25.72%.
| Return on Equity (ROE) | -76.42% |
| Return on Assets (ROA) | -24.13% |
| Return on Invested Capital (ROIC) | -25.72% |
| Return on Capital Employed (ROCE) | -35.00% |
| Revenue Per Employee | $202,292 |
| Profits Per Employee | -$829,751 |
| Employee Count | 209 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Verona Pharma has paid $10.29 million in taxes.
| Income Tax | 10.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +289.06% in the last 52 weeks. The beta is 0.39, so Verona Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | +289.06% |
| 50-Day Moving Average | 62.17 |
| 200-Day Moving Average | 38.74 |
| Relative Strength Index (RSI) | 46.90 |
| Average Volume (20 Days) | 1,122,990 |
Short Selling Information
| Short Interest | 9.85M |
| Short Previous Month | 9.00M |
| Short % of Shares Out | 12.08% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.25 |
Income Statement
In the last 12 months, Verona Pharma had revenue of $42.28 million and -$173.42 million in losses. Loss per share was -$2.16.
| Revenue | 42.28M |
| Gross Profit | 39.70M |
| Operating Income | -151.03M |
| Pretax Income | -123.69M |
| Net Income | -173.42M |
| EBITDA | -149.97M |
| EBIT | -151.03M |
| Loss Per Share | -$2.16 |
Full Income StatementBalance Sheet
The company has $399.76 million in cash and $228.81 million in debt, giving a net cash position of $170.95 million or $2.01 per share.
| Cash & Cash Equivalents | 399.76M |
| Total Debt | 228.81M |
| Net Cash | 170.95M |
| Net Cash Per Share | $2.01 |
| Equity (Book Value) | 204.56M |
| Book Value Per Share | 2.42 |
| Working Capital | 410.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$122.20 million and capital expenditures -$580,000, giving a free cash flow of -$122.78 million.
| Operating Cash Flow | -122.20M |
| Capital Expenditures | -580,000 |
| Free Cash Flow | -122.78M |
| FCF Per Share | -$1.44 |
Full Cash Flow StatementMargins
| Gross Margin | 93.89% |
| Operating Margin | -357.22% |
| Pretax Margin | -385.84% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Verona Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.87% |
| Shareholder Yield | -2.87% |
| Earnings Yield | -3.33% |
| FCF Yield | -2.36% |
Dividend DetailsAnalyst Forecast
The average price target for Verona Pharma is $66.83, which is 6.91% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $66.83 |
| Price Target Difference | 6.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 100.82% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Verona Pharma has an Altman Z-Score of 2.73 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.73 |
| Piotroski F-Score | 1 |